Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer

Gordon, Erlinda M.; Hall, Frederick L.

doi:10.5772/21120

Cited by 3 publications

(1 citation statement)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rexin-G ® , described as the “first targeted molecular genetic injectable medicine”, was approved, blocking the endogenous cyclin G1 protein, disrupting the cell cycle. This drug shows the advantage that it can be used for all metastatic solid tumors, unlike others that cannot be used if they are metastatic [ 194 , 195 ]. Chawla et al showed that growing doses of Rexin-G in metastatic gemcitabine refractory pancreatic adenocarcinoma were able to increase disease-free survival by a few months, revealing that this targetable injectable retroviral vector is safe and exhibits antitumor activity [ 196 ].…”

Section: Walkthrough On Pipeline Productsmentioning

confidence: 99%

Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

Viegas,

Patrício,

Prata

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Pancreatic cancer represents one of the most lethal cancer types worldwide, with a 5-year survival rate of less than 5%. Due to the inability to diagnose it promptly and the lack of efficacy of existing treatments, research and development of innovative therapies and new diagnostics are crucial to increase the survival rate and decrease mortality. Nanomedicine has been gaining importance as an innovative approach for drug delivery and diagnosis, opening new horizons through the implementation of smart nanocarrier systems, which can deliver drugs to the specific tissue or organ at an optimal concentration, enhancing treatment efficacy and reducing systemic toxicity. Varied materials such as lipids, polymers, and inorganic materials have been used to obtain nanoparticles and develop innovative drug delivery systems for pancreatic cancer treatment. In this review, it is discussed the main scientific advances in pancreatic cancer treatment by nano-based drug delivery systems. The advantages and disadvantages of such delivery systems in pancreatic cancer treatment are also addressed. More importantly, the different types of nanocarriers and therapeutic strategies developed so far are scrutinized.

show abstract

Section: Walkthrough On Pipeline Productsmentioning

confidence: 99%

Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

Viegas,

Patrício,

Prata

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Nanopharmaceuticals (part 1): products on the market

Weissig¹,

Pettinger²,

Murdock³

2014

IJN

485

270

View full text Add to dashboard Cite

In 2000, the National Institute of Health launched the National Nanotechnology Initiative to support, coordinate, and advance research and development of nanoscale projects. The impact of this new program on health-science related research and development became quickly visible. Broad governmental financial support advanced the start of new, and the deepening of already existing, interdisciplinary research. The anticipated merger of nanoscience with medicine quickly instigated the conceptualization of nanomedicine. The adoption of nanoscience terminology by pharmaceutical scientists resulted in the advent of nanopharmaceuticals. The term “nano” became tantamount to “cutting-edge” and was quickly embraced by the pharmaceutical science community. Colloidal drug delivery systems reemerged as nanodrug delivery systems; colloidal gold became a suspension of nano gold particles. In this review, we first review nanoscience related definitions applied to pharmaceuticals, we then discuss all 43 currently approved drug formulations which are publicized as nanopharmaceuticals, and finally we analyze clinical aspects of selected drug formulations.

show abstract

Our Journey Beyond Sunset Boulevard: Evidence-Based Analysis of Tumor-Targeted Cancer Gene Therapy Shines a Critical Spotlight on Long-Term Cancer-Free Survival

Hall¹,

Gordon²

2021

Our Journey Beyond Sunset Boulevard - Evidence-Based Analysis of Tumor-Targeted Gene- And Immuno-Therapies Shine a Critical Spo

View full text Add to dashboard Cite

This unique “PERSPECTIVE” on Targeted Genetic Medicine for Cancer represents the third manuscript in a series of medical oncology papers by gene therapy pioneers, Gordon and Hall, a combined medical oncologist’s and layman’s trilogy recorded with the following intents and purposes: (i) documenting significant milestones in clinical oncology for the medical community, (ii) honoring forthright principles of “Informed Consent” for the advanced/refractory oncology patient, and (iii) confronting logical fallacies of popular opinion, in light of recent critical analyses of long-term cancer-free survival data. As with the two previous historical “perspectives,” the authors present noteworthy up-to-date clinical research documenting the successful management of refractory metastatic cancers with tumor-targeted gene therapy vectors—validating “Pathotropic” (disease-seeking) tumor targeting Avant la Lettre. This paper provides additional insights into the molecular and cellular mechanisms of both tumor-targeting and tumor-eradication. As with the prior two papers, the authors utilize the revealing powers of allegory and classic literature, adding shared iconic cinematic experiences of postmodernism at times, to educate, inform, and convey the formidable yet verifiable and important hard-core science (that is, the fundamental chemistries, biophysics, molecular biology, genetics, stem cell biology, regulatory biology, synthetic virology, tumor immunology, clinical oncology, bio-pharmacology, histopathology, and cancer gene therapy) embodied within the “smart” therapeutic nanoparticle, DeltaRex-G: a refined “primal-hunter” & “tumor-killer” that actively seeks out the cryptic/hidden “Biochemical (Jailbreak) Signatures” of metastatic cancers, delivers targeted gene therapy “precisely”totumor cells, and ultimately eradicates both primary and metastatic lesions, including lymphatic metastases. Accomplishment of the “DeltaRex-G Rescue-Mission of 2019” with updated FDA regulatory approvals and sustainable/scalable cGMP bioproduction is considered opportune—while the Right-to-Try experimental therapies legislation in the United States comes face-to-face with the U.S. FDA approval of Expanded Access for DeltaRex-G for advanced pancreatic cancer and sarcoma, and compassionate use for all solid tumors—as such, the authors embrace the legitimate rights of the cancer patient to be more fully informed of such beneficial treatments currently available in the United States.

show abstract

Critical Stages in the Development of the First Targeted, Injectable Molecular-Genetic Medicine for Cancer

Cited by 3 publications

References 134 publications

Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems

Nanopharmaceuticals (part 1): products on the market

Our Journey Beyond Sunset Boulevard: Evidence-Based Analysis of Tumor-Targeted Cancer Gene Therapy Shines a Critical Spotlight on Long-Term Cancer-Free Survival

Contact Info

Product

Resources

About